Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone for chronic subdural hematoma (non-severe) – randomized phase 3 trial
2015-000927-96Phase 3Completed
- Sponsor
- CHU Rennes
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylprednisolone in Chronic subdural haematoma (CSDH) (2 arms), sponsored by CHU Rennes. Primary endpoint: rate of surgical treatment of the chronic subdural hematoma. Started Jul 2015; status: completed.
02
Drugs
methylprednisolone
03
Conditions
Chronic subdural haematoma (CSDH)
Beyond the preview
Go deeper on 2015-000927-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000927-96.